Abstract:Background/Objectives: Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic disease of the liver that symptomatically can present with pruritus and fatigue. Its established first- and second-line therapies are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) although they provide limited symptom management. Liver transplantation offers a potentially curative therapeutic option in refractory cases progressing to cirrhosis. Novel research published after the current guidelines highlights the importance of providing an up-to-date analysis of treatment options available. Methods: In this study, we conducted a literature search using Pubmed, Ovid Medline, and SCOPUS to provide a narrative review of first-line, second-line, and emerging therapies in PBC. Results: UDCA has been well established as a long-term, safe therapy within the literature although it is possible that treatment dosage can be further optimised in refractory patients. It has a favourable side effect profile. Despite improving biochemical markers, histopathological profile, and overall outcomes, up to 30–40% of patients are refractory to it. Age and sex are highlighted as independent indicators of non-responsiveness. This necessitates effective second-line therapies. Future trials could aim to investigate UDCA as a co-first-line therapy. Further supporting results for OCA were found in the interim extension trial of the seminal POISE study. The long-term phase 4 COBOLT trial is still awaiting results to further assess the complications, adherence, and potential adverse effects. It is a viable option in UDCA-refractory patients. The high incidence rate of dose-related pruritis indicates that alternative second-line options are needed. Bezafibrate is an off-label antilipemic agent that shows promise as a prospective second-line therapy option. The landmark BEZURSO trial alleviated some efficacy and safety concerns, but it remains associated with elevated serum creatinine; thus, it should be considered with caution. Other prospective second-line therapies are budesonide, triple therapy, and novel agents such as seladelpar and elafibranor. Conclusions: UDCA should remain the treatment of choice for PBC, though perhaps not as monotherapy. With further investigation, BF shows promise as a new second-line therapy alongside OCA, which it may outperform.

Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

[Clinical and Pathological Characteristics of Primary Biliary Cirrhosis].

Association of Liver Disease and Chronic Pruritus: A Case–Control Study

Primary biliary cirrhosis:an analysis of 76 cases

Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis

[Primary biliary cholangitis. Experience in 179 patients]

Fatigue in chronic hepatitis B patients is significant and associates with autonomic dysfunction

[Clinical Analysis of Primary Biliary Cirrhosis: a Report of 42 Cases].

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis

Retrospective study and meta-analysis:the clinical features of patients with primary biliary cirrhosis in recent 20 years in China

Extrahepatic manifestations of cholestasis

Fatigue is not influenced by chronotype and is reported to be mainly muscular in patients with primary biliary cholangitis

Comorbidities, mortality and metabolic profile in individuals with primary biliary cholangitis—A Phenome‐Wide‐Association‐Study

Symptom severity reflected by NYHA grade is independently associated with pruritus in chronic heart failure patients

New Treatment Paradigms in Primary Biliary Cholangitis